Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sorivudine · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Sorivudine | DRUG | - |
Inclusion Criteria Patients must have: * HIV infection. * Cutaneous, visceral, or ocular varicella-zoster viral infection. * Refractory or intolerant to acyclovir or foscarnet therapy. * Consent of parent or guardian. Exclusion Criteria Co-existing Condition: Patients with the following symptom...
Top 20 of 28 competitors
Sorivudine is an investigational small molecule being studied for the treatment of varicella-zoster viral disease (VZV), including chickenpox, in HIV-infected children who have not had success with or cannot take other treatments for VZV. It is being developed by Bristol-Myers Squibb Company.
Sorivudine is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The drug is an investigational small molecule in Phase 3 clinical development for the treatment of varicella-zoster viral disease in HIV-infected children.
Sorivudine is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for the treatment of varicella-zoster viral disease in HIV-infected children who have not had success with or cannot take other treatments.
Sorivudine has one completed Phase 3 clinical trial, identified as NCT00002358. The trial studied BV-araU in the treatment of varicella-zoster viral disease in HIV-infected children aged 2 years and older in the United States. The trial was uncontrolled and did not use randomization or blinding.
Yes, Sorivudine is also known as BV-araU. The clinical trial NCT00002358, which studied the drug for varicella-zoster viral disease in HIV-infected children, refers to the treatment as BV-araU. This alternative name is used in the trial title and description.